News | February 16, 2024
Glenmark Pharma posts Q3 FY24 net loss of Rs. 331 Cr
he lower sales in the current quarter are mainly on account of a one?time impact on the company’s India business
he lower sales in the current quarter are mainly on account of a one?time impact on the company’s India business
Gross profit was Rs. 313.3 crore, up by +30.4% YoY with a Gross margin of 53.5%
It is indicated for the inhibition of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation
Bromfenac Ophthalmic Solution 0.075% (RLD BromSite) had estimated annual sales of USD 15 million in the U.S.
Dexamethasone is used to treat conditions such as arthritis, blood/hormone disorders, allergic reactions
EBITDA for Q3 FY24 almost tripled to reach Rs. 41.49 crore
Revenue from Operations stood at Rs. 2,607 crore, 25% YoY growth. Domestic revenue at Rs. 2,400 crore, 20% YoY growth and export revenue at Rs. 207 crore, 118% YoY growth
Glenmark will be responsible for further developing, registering, and commercializing Envafolimab in India, Asia Pacific, Middle East and Africa, Russia, CIS, and Latin America
Gabapentin is indicated for the management of Postherpetic Neuraligia
Aarti Drugs has reported total income of Rs. 607.61 crores during the period ended December 31, 2023
Subscribe To Our Newsletter & Stay Updated
